相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Robotic Resection of Gallbladder Cancer: A Single-Center Retrospective Comparative Study to Open Resection
Christoph Tschuor et al.
AMERICAN SURGEON (2023)
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study
Jean marc Phelip et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1
Do-Youn Oh et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Adjuvant S-1 versus observation in curatively resected biliary tract cancer: A phase III trial (JCOG1202: ASCOT)
Masafumi Ikeda et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
S3-Guideline: Diagnosis and Therapy of Hepatocellular Carcinoma
S. Voesch et al.
ZEITSCHRIFT FUR GASTROENTEROLOGIE (2022)
Adjuvant radiotherapy improves long-term survival after resection for gallbladder cancer A population-based cohort study
Sivesh K. Kamarajah et al.
EJSO (2022)
Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial
Akihiro Ohba et al.
FUTURE ONCOLOGY (2022)
Palliation in Gallbladder Cancer: The Role of Gastrointestinal Endoscopy
Tommaso Schepis et al.
CANCERS (2022)
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial).
Akihiro Ohba et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Defining and Predicting Early Recurrence after Resection for Gallbladder Cancer
Kota Sahara et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Efficacy of Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line Treatment in Patients With Advanced Gallbladder Cancer A Multicenter Phase 2 Randomized Clinical Trial (GB-SELECT)
Anant Ramaswamy et al.
JAMA ONCOLOGY (2021)
Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin
Hyehyun Jeong et al.
CANCERS (2021)
The Clinical Management of Cholangiocarcinoma in the United States and Europe: A Comprehensive and Evidence-Based Comparison of Guidelines
Zhi Ven Fong et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Chemotherapy for advanced gallbladder cancer (GBC): A systematic review and meta-analysis
Alexander A. Azizi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Gallbladder Cancer: Current Insights in Genetic Alterations and Their Possible Therapeutic Implications
Hendrien Kuipers et al.
CANCERS (2021)
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
Angela Lamarca et al.
LANCET ONCOLOGY (2021)
A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy
In Sil Choi et al.
EUROPEAN JOURNAL OF CANCER (2021)
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
Milind Javle et al.
LANCET ONCOLOGY (2021)
Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study
Toshihiko Doi et al.
CANCER MEDICINE (2021)
Use of indocyanine green (ICG) augmented near-infrared fluorescence imaging in robotic radical resection of gallbladder adenocarcinomas
Ali Ahmad
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES (2020)
Re-resection in Incidental Gallbladder Cancer: Survival and the Incidence of Residual Disease
Elise A. J. de Savornin Lohman et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Comparison of oncological outcomes after open and laparoscopic re-resection of incidental gallbladder cancer
E. A. Vega et al.
BRITISH JOURNAL OF SURGERY (2020)
MYC, MYCL, and MYCN as therapeutic targets in lung cancer
Daniel Masso-Valles et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2020)
Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Shannon Lee et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Effectiveness of Olaparib Treatment in a Patient with Gallbladder Cancer with an ATM-Inactivating Mutation
Wei Zhang et al.
ONCOLOGIST (2020)
Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
Ufuk Degirmenci et al.
CELLS (2020)
Role of tumour location and surgical extent on prognosis in T2 gallbladder cancer: an international multicentre study
W. Kwon et al.
BRITISH JOURNAL OF SURGERY (2020)
Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer
Richard D. Kim et al.
EUROPEAN JOURNAL OF CANCER (2020)
Molecular targeted therapies: Ready for prime time in biliary tract cancer
Angela Lamarca et al.
JOURNAL OF HEPATOLOGY (2020)
Comparison of overall survival in gallbladder carcinoma at academic versus community cancer centers: An analysis of the National Cancer Data Base
Chrissy Liu et al.
JOURNAL OF SURGICAL ONCOLOGY (2020)
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
Richard D. Kim et al.
JAMA ONCOLOGY (2020)
Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis
Maolan Li et al.
GUT (2019)
Major hepatectomy with or without pancreatoduodenectomy for advanced gallbladder cancer
T. Mizuno et al.
BRITISH JOURNAL OF SURGERY (2019)
The role of neoadjuvant chemotherapy or chemoradiotherapy for advanced gallbladder cancer - A systematic review
Abdul R. Hakeem et al.
EJSO (2019)
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
John N. Primrose et al.
LANCET ONCOLOGY (2019)
Lymphatic spread of T2 gallbladder carcinoma: Regional lymphadenectomy is required independent of tumor location
Koji Toge et al.
EJSO (2019)
Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.
Yung-Jue Bang et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial
Rachna T. Shroff et al.
JAMA ONCOLOGY (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
PLAC8 overexpression correlates with PD-L1 upregulation and acquired resistance to chemotherapies in gallbladder carcinoma
Ke Gong et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
Makoto Ueno et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Systematic review of management of incidental gallbladder cancer after cholecystectomy
K. Soreide et al.
BRITISH JOURNAL OF SURGERY (2019)
A Phase 2 Trial of Regorafenib as a Single Agent in Patients With Chemotherapy-Refractory, Advanced, and Metastatic Biliary Tract Adenocarcinoma
Weijing Sun et al.
CANCER (2019)
Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study
Jean-Marc Phelip et al.
DIGESTIVE AND LIVER DISEASE (2019)
Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer
Changqing Xie et al.
HEPATOLOGY (2019)
Modified gemcitabine and oxaliplatin or gemcitabine plus cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial
Atul Sharma et al.
EUROPEAN JOURNAL OF CANCER (2019)
Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets
Benjamin A. Weinberg et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2019)
Epidemiology of gallbladder cancer
Prashanth Rawla et al.
CLINICAL AND EXPERIMENTAL HEPATOLOGY (2019)
Gallbladder cancer: epidemiology and genetic risk associations
Mikayla A. Schmidt et al.
CHINESE CLINICAL ONCOLOGY (2019)
Hepatopancreaticoduodenectomy for Biliary Cancer Strategies for Near-zero Operative Mortality and Acceptable Long-term Outcome
Taku Aoki et al.
ANNALS OF SURGERY (2018)
Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer
T. Ebata et al.
BRITISH JOURNAL OF SURGERY (2018)
Chemoradiotherapy Versus Chemotherapy Alone for Unresected Nonmetastatic Gallbladder Cancer: National Practice Patterns and Outcomes
Vivek Verma et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
EGFR Target Therapy Combined with Gemox for Advanced Biliary Tract Cancers: a Meta-analysis based on RCTs
Wen Cai et al.
JOURNAL OF CANCER (2018)
Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
Jingjing Duan et al.
CANCER MEDICINE (2018)
Variations in DNA repair genomic alterations and tumor mutation burden in biliary tract cancer (BTC) subtypes.
Reham Abdel-Wahab et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Investigation of targetable predictive and prognostic markers in gallbladder carcinoma
Azfar Neyaz et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2018)
Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine
Masafumi Ikeda et al.
CANCER SCIENCE (2018)
M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-beta, in Asian patients with advanced solid tumors.
Yutaka Fujiwara et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Biliary carcinogenesis in pancreaticobiliary maljunction
Terumi Kamisawa et al.
JOURNAL OF GASTROENTEROLOGY (2017)
Adjuvant Therapy for Resected Gallbladder Cancer: Analysis of the National Cancer Data Base
Kalyan C. Mantripragada et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Adjuvant Therapy for Resected Gallbladder Cancer: Analysis of the National Cancer Data Base
Kalyan C. Mantripragada et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Does radiotherapy still have a role in unresected biliary tract cancer?
Erqi L. Pollom et al.
CANCER MEDICINE (2017)
Precision medicine for gallbladder cancer using somatic copy number amplifications (SCNA) and DNA repair pathway gene alterations.
Milind M. Javle et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update
Aarti Sharma et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
New Horizons for Precision Medicine in Biliary Tract Cancers
Juan W. Valle et al.
CANCER DISCOVERY (2017)
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Ping Wee et al.
CANCERS (2017)
New molecular and immunotherapeutic approaches in biliary cancer
David Goldstein et al.
ESMO OPEN (2017)
Comparative Analysis of Mutational Profile of Sonic hedgehog Gene in Gallbladder Cancer
Ruhi Dixit et al.
DIGESTIVE DISEASES AND SCIENCES (2017)
Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. W. Valle et al.
ANNALS OF ONCOLOGY (2016)
Neoadjuvant Chemoradiation Followed by Surgery for Locally Advanced Gallbladder Cancers: A New Paradigm
Reena Engineer et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Biliary Cancer: Utility of Next-Generation Sequencing for Clinical Management
Milind Javle et al.
CANCER (2016)
Somatic Mutations of PI3K in Early and Advanced Gallbladder Cancer Additional Options for an Orphan Cancer
Ivan Roa et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2016)
Epidermal growth factor receptor (EGFR) in Biliary tract cancer
R.V. Gomes et al.
HPB (2016)
The association between BMI and gallbladder cancer risk: a meta-analysis
Zhan-Ming Li et al.
ONCOTARGET (2016)
Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations
Lorena Marcano-Bonilla et al.
CHINESE CLINICAL ONCOLOGY (2016)
Surgical management of biliary tract cancers
Mark Fairweather et al.
CHINESE CLINICAL ONCOLOGY (2016)
Myc and cell cycle control
Gabriel Bretones et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2015)
Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis
Ning Ma et al.
BMC CANCER (2015)
HER2 expression status in diverse cancers: review of results from 37,992 patients
Min Yan et al.
CANCER AND METASTASIS REVIEWS (2015)
Biliary tract cancers: SEOM clinical guidelines
M. Benavides et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2015)
Natural history of metastatic biliary tract cancer (BTC) patients with good performance status (PS) who were treated with only best supportive care (BSC)
Jun Ho Ji et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2015)
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Edgar Ben-Josef et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Gallbladder carcinoma: prognostic factors and therapeutic options
Thorsten Oliver Goetze
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Gallbladder Cancer: expert consensus statement
Thomas A. Aloia et al.
HPB (2015)
Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer
Daniel H. Ahn et al.
SCIENTIFIC REPORTS (2015)
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study
A. Santoro et al.
ANNALS OF ONCOLOGY (2015)
Deregulation of MYC and TP53 through genetic and epigenetic alterations in gallbladder carcinomas
Geraldo Ishak et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2015)
Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials
J. W. Valle et al.
ANNALS OF ONCOLOGY (2014)
A genetic model for gallbladder carcinogenesis and its dissemination
S. G. Barreto et al.
ANNALS OF ONCOLOGY (2014)
S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma
A. B. El-Khoueiry et al.
BRITISH JOURNAL OF CANCER (2014)
Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Federation Francophone de Cancerologie Digestive 9902 phase II randomised study
Jean-Marc Phelip et al.
EUROPEAN JOURNAL OF CANCER (2014)
Exploiting DNA mismatch repair deficiency as a therapeutic strategy
Delphine Guillotin et al.
EXPERIMENTAL CELL RESEARCH (2014)
Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors
Brian A. Costello et al.
INVESTIGATIONAL NEW DRUGS (2014)
BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma
Benjamin Goeppert et al.
MODERN PATHOLOGY (2014)
EGF receptor trafficking: consequences for signaling and cancer
Alejandra Tomas et al.
TRENDS IN CELL BIOLOGY (2014)
Role of aberrant PI3K pathway activation in gallbladder tumorigenesis
Andrea Lunardi et al.
ONCOTARGET (2014)
A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study
Jun Ho Yi et al.
EUROPEAN JOURNAL OF CANCER (2012)
Adjuvant Therapy in the Treatment of Biliary Tract Cancer: A Systematic Review and Meta-Analysis
Anne M. Horgan et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Accurate Staging for Gallbladder Cancer Implications for Surgical Therapy and Pathological Assessment
Hiromichi Ito et al.
ANNALS OF SURGERY (2011)
Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer
Allyson J. Ocean et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202
Syma Iqbal et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
The Role of Antiangiogenetic Agents in the Treatment of Breast Cancer
M. A. Bareschino et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Outcomes of Radical Surgery for Gallbladder Cancer Patients with Lymphatic Metastases
Hua Meng et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2011)
Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
Tanios Bekaii-Saab et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prognostic impact of vascular endothelial growth factor-A expression in resected gallbladder carcinoma
Xiao-Nan Sun et al.
TUMOR BIOLOGY (2011)
Systematic review on the surgical treatment for T1 gallbladder cancer
Seung Eun Lee et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial
C. Bengala et al.
BRITISH JOURNAL OF CANCER (2010)
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
T. Okusaka et al.
BRITISH JOURNAL OF CANCER (2010)
Best Supportive Care Compared With Chemotherapy for Unresectable Gall Bladder Cancer: A Randomized Controlled Study
Atul Sharma et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study
Kerry J. Williams et al.
HPB (2010)
Epidemiology of biliary tract cancers: an update
G. Randi et al.
ANNALS OF ONCOLOGY (2009)
Analysis of the Extent of Resection for Adenocarcinoma of the Gallbladder
Michael D'Angelica et al.
ANNALS OF SURGICAL ONCOLOGY (2009)
Pancreaticobiliary maljunction and carcinogenesis to biliary and pancreatic malignancy
Takahiko Funabiki et al.
LANGENBECKS ARCHIVES OF SURGERY (2009)
Gallbladder cancer — A comprehensive review
C.H. Eric Lai et al.
SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND (2009)
Gallbladder disease in patients with primary sclerosing cholangitis
Karouk Said et al.
JOURNAL OF HEPATOLOGY (2008)
Surgery for gallbladder cancer: A population-based analysis
Natalie G. Coburn et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2008)
Phase II study of erlotinib in patients with advanced biliary cancer
Philip A. Philip et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma - A north central cancer treatment group phase II trial
SR Alberts et al.
CANCER (2005)
Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma
T Takada et al.
CANCER (2002)
CPT-11 for bile-duct and gallbladder carcinoma - A phase II north central cancer treatment group (NCCTG) study
SR Alberts et al.
JOURNAL OF GASTROINTESTINAL CANCER (2002)
Epidemiology and molecular pathology of gallbladder cancer
EC Lazcano-Ponce et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2001)
Gallstones and gall bladder carcinoma
L Vitetta et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY (2000)
分享论文
